Business Description
Outlook Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US68235M1053
Description
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.98 | |||||
| Equity-to-Asset | -1.78 | |||||
| Debt-to-Equity | -0.39 | |||||
| Debt-to-EBITDA | 25.57 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 22.8 | |||||
| 3-Year EPS without NRI Growth Rate | 29 | |||||
| 3-Year FCF Growth Rate | 26.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 54.78 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.55 | |||||
| 9-Day RSI | 24.33 | |||||
| 14-Day RSI | 22.95 | |||||
| 6-1 Month Momentum % | -32.3 | |||||
| 12-1 Month Momentum % | -40.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | |||||
| Quick Ratio | 1.07 | |||||
| Cash Ratio | 0.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27 | |||||
| Shareholder Yield % | -209.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -229.89 | |||||
| ROIC % | -155.68 | |||||
| ROC (Joel Greenblatt) % | 103.82 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 28.96 | |||||
| EV-to-EBITDA | 26.79 | |||||
| EV-to-Forward-Revenue | 4.28 | |||||
| EV-to-FCF | -0.53 | |||||
| Earnings Yield (Greenblatt) % | 3.45 | |||||
| FCF Yield % | -185.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OTLK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Outlook Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -10.77 | ||
| Beta | -0.58 | ||
| Volatility % | 88.49 | ||
| 14-Day RSI | 22.95 | ||
| 14-Day ATR ($) | 0.296739 | ||
| 20-Day SMA ($) | 1.75075 | ||
| 12-1 Month Momentum % | -40.56 | ||
| 52-Week Range ($) | 0.87 - 12.8499 | ||
| Shares Outstanding (Mil) | 23.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Outlook Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Outlook Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Outlook Therapeutics Inc Frequently Asked Questions
What is Outlook Therapeutics Inc(OTLK)'s stock price today?
The current price of OTLK is $1.47. The 52 week high of OTLK is $12.85 and 52 week low is $0.87.
When is next earnings date of Outlook Therapeutics Inc(OTLK)?
The next earnings date of Outlook Therapeutics Inc(OTLK) is 2024-12-27 Est..
Does Outlook Therapeutics Inc(OTLK) pay dividends? If so, how much?
Outlook Therapeutics Inc(OTLK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers